Welcome to our dedicated page for Revvity news (Ticker: RVTY), a resource for investors and traders seeking the latest updates and insights on Revvity stock.
Revvity, Inc. reports developments for a global life sciences and diagnostics business that provides health science solutions, technologies, expertise and services across workflows from discovery and development to detection and diagnosis. Company updates center on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and Signals software for pharmaceutical, biotechnology, diagnostic laboratory, academic and government customers.
Recurring announcements include financial results and earnings calls, quarterly dividends, investor conference presentations, governance matters and product introductions. Recent product themes include Signals BioDesign for biologics construct design and research collaboration, Signals One platform integration, high-content imaging, multimode detection, sample preparation, screening and laboratory automation systems.
Summary not available.
Revvity (NYSE: RVTY) will present at two investor conferences in spring 2026: the BofA Securities 2026 Health Care Conference on May 13, 2026 and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026.
Presenters include Steve Willoughby (SVP, investor relations, ESG, risk) and Prahlad Singh (president and CEO). Live audio webcasts will be available on the company's Events page, with replays posted to Revvity Investor Relations and accessible for at least 30 days.
Revvity (NYSE: RVTY) will release Q1 2026 financial results before market open on Tuesday, May 5, 2026.
The company will host a conference call the same day at 7:30 a.m. ET with Prahlad Singh, president and CEO, and Max Krakowiak, CFO. A live audio webcast will be available on the company's Investors website.
Revvity (NYSE: RVTY) launched Signals BioDesign, a cloud-native molecular cloning platform for biotech and pharma R&D teams on April 9, 2026. The solution supports Golden Gate, Gibson assembly, restriction/ligation, primer design, Sanger sequencing analysis, protein translation, and high-throughput combinatorial cloning up to 1,000 constructs.
Signals BioDesign integrates with the Signals One platform for unified bioregistration and experiment capture, adds real-time team collaboration, centralized sequence libraries, duplicate checking, granular access controls, multi-tenant SaaS deployment, and an AI-ready data infrastructure for future ML applications.
Revvity (NYSE: RVTY) will present at three investor conferences in early March 2026: Raymond James on March 2, TD Cowen on March 3, and Barclays on March 10.
Executives presenting include Max Krakowiak, CFO, and Prahlad Singh, CEO. Live audio webcasts and on‑demand replays will be available on the company’s Events/Investor Relations website for at least 30 days.
Revvity (NYSE: RVTY) unveiled multiple discovery platforms at SLAS2026 (Feb 7–11), including the Opera Phenix OptIQ high-content screening system, the EnVision Nexus One multimode plate reader, and the AssayMate workstation.
Highlights: improved camera quantum efficiency (60% to 95%), expanded AI image analysis, TRF/Alpha/luminescence sensitivity, 3–1000 µL liquid handling, and 21 CFR Part 11 compliance tools.
Revvity (NYSE: RVTY) reported Q4 2025 revenue of $772 million (6% growth) and GAAP EPS of $0.87. Adjusted EPS from continuing operations was $1.70. Full year 2025 revenue was $2.856 billion with GAAP EPS $2.07 and adjusted EPS $5.06. The company initiated 2026 guidance of $2.96–2.99 billion revenue and adjusted EPS $5.35–$5.45.
Revvity (NYSE: RVTY) announced a regular quarterly dividend of $0.07 per share on common stock, declared on January 26, 2026. The dividend is payable on May 8, 2026 to shareholders of record at the close of business on April 17, 2026. This provides a scheduled cash distribution to current shareholders on the stated record and payment dates.
Revvity (NYSE: RVTY) said it will release fourth-quarter and full-year 2025 results before market open on February 2, 2026 and will host a conference call at 8:00 a.m. ET. Preliminary Q4 2025 revenue is expected to be approximately $772 million with reported and organic growth of ~6% and ~4%, respectively. Full-year 2025 revenue is expected to be approximately $2,855 million with reported and organic growth of ~4% and ~3%. The company now expects full-year adjusted EPS to exceed the upper end of the prior $4.90–$5.00 guidance. The release notes use of non-GAAP measures and that adjusted EPS cannot be reconciled to GAAP without unreasonable effort.
Revvity (NYSE: RVTY) announced a collaboration with Eli Lilly to make Lilly TuneLab predictive models available through the Signals Xynthetica offering, creating a federated framework to accelerate AI-enabled drug discovery. The integration lets participating biotechs apply Lilly’s models inside the Signals platform while keeping proprietary data private via federated learning and Revvity’s Models-as-a-Service approach. Revvity’s Signals One and Signals Synergy modules provide data capture, analytics, and secure exchange to support the network. Lilly and Revvity will jointly fund access for selected participants, including software access and modeling credits, aimed at lowering barriers to AI adoption across the biotech ecosystem.